208,276 Shares in LivaNova PLC (NASDAQ:LIVN) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 208,276 shares of the company’s stock, valued at approximately $9,645,000.

Several other large investors have also made changes to their positions in LIVN. Atria Investments Inc boosted its position in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after acquiring an additional 331 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of LivaNova during the 3rd quarter worth approximately $292,000. Segall Bryant & Hamill LLC acquired a new stake in shares of LivaNova during the 3rd quarter worth approximately $2,127,000. Intech Investment Management LLC boosted its position in shares of LivaNova by 80.4% during the 3rd quarter. Intech Investment Management LLC now owns 15,815 shares of the company’s stock worth $831,000 after acquiring an additional 7,049 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock valued at $32,678,000 after purchasing an additional 93,311 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

LIVN has been the subject of several research reports. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group dropped their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, Mizuho dropped their price objective on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $61.17.

LivaNova Stock Down 2.3 %

Shares of NASDAQ LIVN opened at $39.48 on Friday. The stock has a market capitalization of $2.15 billion, a P/E ratio of 94.00 and a beta of 1.10. The company has a 50-day moving average price of $45.31 and a 200-day moving average price of $48.75. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.